The company’s stock fell by more than 40 percent Friday after the approval of Lyfgenia, the release of its pricing, and comparison to a less expensive gene-edited drug approved the same day.
The first gene therapies for sickle cell disease are now approved: Casgevy from Vertex Pharmaceuticals Casgevy and Lyfgenia from Bluebird Bio. Despite the same-day approval, key differences give one of these therapies commercialization advantages over the other.
StockWatch: Verve Investors Accentuate the Negative as Shares Tumble, Then Recover genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Novartis gains global rights to Legend Biotech cell therapies that address DLL3, a promising target for lung cancers and other types of solid tumors. The pharmaceutical giant may make these therapies using T-Charge, its next-generation CAR T-cell therapy manufacturing technology.
Eli Lilly is acquiring Beam Therapeutics’ opt-in rights to three Verve Therapeutics gene-editing therapies for cardiovascular conditions. The deal comes four months after the pharmaceutical giant began a partnership on a preclinical Verve gene-editing therapy for a different target.